7-nicotinoylheptanoic acid | 95854-01-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: 7-nicotinoylheptanoic acid
• 英文别名: 8-oxo-8-pyridin-3-yloctanoic acid
• CAS: 95854-01-6
• 化学式: C₁₃H₁₇NO₃
• 分子量: 235.283
• InChiKey: LTINGCSDSVQJFN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  17
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  67.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-nicotinoylheptanoic acid 生成 2-(pyridin-3-yl)-3-[5-(ethoxycarbonyl)-pentyl]-indole
  参考文献：
  名称：

  RENFROE, H. B.

  摘要：

  DOI：
• 作为产物：
  描述：

  甲基8-氯-8-氧代辛酸 在 sodium hydroxide 、 正丁基锂 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 正己烷 为溶剂， 反应 3.5h， 生成 7-nicotinoylheptanoic acid
  参考文献：
  名称：

  Structurally Simple Trichostatin A-Like Straight Chain Hydroxamates as Potent Histone Deacetylase Inhibitors

  摘要：

  A series of new, structurally simple trichostatin A (TSA)-like straight chain hydroxamates were prepared and evaluated for their ability to inhibit partially purified human histone deacetylase 1 (HDAC-1). Some of these compounds such as 8m, 8n, 12, and 15b exhibited potent HDAC inhibitory activity with low nanomolar IC50 values, comparable to natural TSA. These compounds induce hyperacetylation of histones in T24 human cancer cells and significantly inhibit proliferation in. various human cancer cells. They also induce expression of p21 and cause cell cycle blocks in human cancer cells. in this paper, we describe the synthesis of these new compounds as well as structure-activity relationship results from enzyme inhibition and alterations in cellular function.

  DOI：

  10.1021/jm020154k

文献信息

• 3-Substituted-2-(heteroaryl) indoles
  申请人：Ciba-Geigy Corporation

  公开号：US04511573A1

  公开（公告）日：1985-04-16

  Disclosed as thromboxane synthetase inhibitors are the compounds of formula ##STR1## wherein R.sub.1 represents hydrogen or lower alkyl; Ar represents 3-pyridyl or 1-imidazolyl, each unsubstituted or substituted by lower alkyl, carboxy, lower alkoxycarbonyl or carbamoyl; R.sub.2 and R.sub.3 independently represent hydrogen, lower alkyl, halogen, trifluoromethyl, hydroxy, lower alkoxy, carboxy lower alkyl, lower alkoxycarbonyl lower alkyl, carboxy, lower alkoxycarbonyl, or lower alkyl-(thio, sulfinyl or sulfonyl), or R.sub.2 and R.sub.3 together on adjacent carbon atoms represent lower alkylenedioxy; A represents straight chain or branched alkylene of 3 to 12 carbon atoms in which the number of the carbon atoms separating the indole nucleus from group B is 3 to 12, straight chain or branched alkenylene of 2 to 12 carbon atoms, straight chain or branched alkynylene of 2 to 12 carbon atoms, lower alkylenephenylene-lower (alkylene or alkenylene), lower alkylenephenylene, lower alkylene-(thio or oxy)-lower alkylene, lower alkylene-(thio or oxy)-phenylene, or lower alkylene-phenylene-(thio or oxy)-lower alkylene; B represents carboxy, esterified carboxy, carbamoyl, mono- or di-lower alkylcarbamoyl, hydroxymethyl, cyano, hydroxycarbamoyl, 5-tetrazolyl or formyl; the imidazolyl and pyridyl N-oxide thereof; or a pharmaceutically acceptable salt thereof; as well as their synthesis, pharmaceutical compositions thereof, and methods of treatment utilizing such compounds.

  作为血栓素合成酶抑制剂的化合物公开为式##STR1##其中R.sub.1代表氢或较低的烷基；Ar代表3-吡啶基或1-咪唑基，每个未取代或被较低的烷基，羧基，较低的烷氧羰基或氨基取代；R.sub.2和R.sub.3独立地代表氢，较低的烷基，卤素，三氟甲基，羟基，较低的烷氧基，羧基较低的烷基，较低的烷氧羰基较低的烷基，羧基，较低的烷氧羰基，或较低的烷基-(硫，亚硫酰基或磺酰基)，或R.sub.2和R.sub.3在相邻碳原子上一起代表较低的烷二氧基；A代表直链或支链的3到12个碳原子的烷基，其中将吲哚核与B基团分隔的碳原子数为3到12，直链或支链的2到12个碳原子的烯基，直链或支链的2到12个碳原子的炔基，较低的烷基苯基-较低的(烷基或烯基)，较低的烷基苯基，较低的烷基-(硫或氧)-较低的烷基，较低的烷基-(硫或氧)-苯基，或较低的烷基-苯基-(硫或氧)-较低的烷基；B代表羧基，酯化羧基，氨基甲酰基，单或双较低的烷基氨基甲酰基，氢氧甲基，氰基，羟基甲酰基，5-四唑基或甲酰基；其咪唑基和吡啶基N-氧化物；或其药学上可接受的盐；以及它们的合成，药物组成物，以及利用这类化合物的治疗方法。
• Inhibitors of histone deacetylase
  申请人：——

  公开号：US20020115826A1

  公开（公告）日：2002-08-22

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及组蛋白去乙酰化酶的抑制。本发明提供了用于抑制组蛋白去乙酰化酶酶活性的化合物和方法。本发明还提供了用于治疗细胞增殖性疾病和状况的组合物和方法。
• Inhibitors of Histone Deacetylase
  申请人：Delorme Daniel

  公开号：US20090181971A1

  公开（公告）日：2009-07-16

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及抑制组蛋白去乙酰化酶的技术。本发明提供了抑制组蛋白去乙酰化酶酶活性的化合物和方法。本发明还提供了治疗细胞增殖性疾病和病状的组合物和方法。
• INHIBITORS OF HISTONE DEACETYLASE
  申请人：Methylgene, Inc.

  公开号：EP1280764B1

  公开（公告）日：2010-11-24
• US4511573A
  申请人：——

  公开号：US4511573A

  公开（公告）日：1985-04-16